Collegium Pharmaceutical, Inc. COLL Belbuca — Finite-Lived Intangible Assets, Net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, net?
- Collegium Pharmaceutical, Inc. (COLL) reported belbuca — finite-lived intangible assets, net of $56.54M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, net changed year-over-year?
- Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, net decreased by 57.1% year-over-year, from $131.94M to $56.54M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, net?
- Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s belbuca — finite-lived intangible assets, net has grown at a -32.2% compound annual growth rate (CAGR), from $1.33B to $414.66M.
- What does belbuca — finite-lived intangible assets, net mean?
- The carrying value of Belbuca-related intangible assets on the balance sheet, calculated as the gross cost minus accumulated amortization and any impairment charges. It represents the remaining unamortized economic value of the product's intellectual property.